Tags

Type your tag names separated by a space and hit enter

In vitro profiling of antimethicillin-resistant Staphylococcus aureus activity of thymoquinone against selected type and clinical strains.
Lett Appl Microbiol. 2016 Mar; 62(3):283-9.LA

Abstract

This study explores antimethicillin-resistant Staphylococcus aureus (MRSA) activity of a bioactive phytochemical constituent, thymoquinone obtained from the medicinal herb, Nigella sativa Linn. Based on initial assessment on crude extract of seeds of Nigella sativa Linn, the pure active constituent was employed in the study. A total of 99 MRSA strains which comprised of 40 types and 59 clinical strains were selected for the study. Minimum inhibitory concentration (MIC), bactericidal activity, postantibiotic effect (PAE) and propensity to select resistant mutants were determined using standard protocols. Results revealed that thymoquinone exhibited MIC in the range of 8-16 μg ml(-1) and MIC90 of 16 μg ml(-1) against MRSA strains. It was bactericidal to MRSA by demonstrating >3 log kill. It showed a longer PAE of 3·2 ± 0·2 h. Upon exposure to high-density inoculum of MRSA, it did not select resistant mutants. Transmission electron microscopy of thymoquinone-treated MRSA showed no lysis but damage to cell wall and cell membrane which corroborated well with the salt tolerance and bacteriolysis assays. In conclusion, MIC90 , bactericidal property, longer PAE, absence of resistant mutant selection and damages in cell membrane and cell wall imply a promising anti-MRSA activity of thymoquinone.

SIGNIFICANCE AND IMPACT OF THE STUDY

This is the first detailed report on anti-MRSA activity of thymoquinone. The assessment was made with both type and clinical strains. Thymoquinone may be a potential lead compound which can be further optimized to discover novel anti-MRSA agents.

Authors+Show Affiliations

Orchid Chemicals and Pharmaceuticals Ltd., Chennai, India.Orchid Chemicals and Pharmaceuticals Ltd., Chennai, India.Microbiology Division, CSIR-CLRI, Chennai, India.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

26743923

Citation

Hariharan, P, et al. "In Vitro Profiling of Antimethicillin-resistant Staphylococcus Aureus Activity of Thymoquinone Against Selected Type and Clinical Strains." Letters in Applied Microbiology, vol. 62, no. 3, 2016, pp. 283-9.
Hariharan P, Paul-Satyaseela M, Gnanamani A. In vitro profiling of antimethicillin-resistant Staphylococcus aureus activity of thymoquinone against selected type and clinical strains. Lett Appl Microbiol. 2016;62(3):283-9.
Hariharan, P., Paul-Satyaseela, M., & Gnanamani, A. (2016). In vitro profiling of antimethicillin-resistant Staphylococcus aureus activity of thymoquinone against selected type and clinical strains. Letters in Applied Microbiology, 62(3), 283-9. https://doi.org/10.1111/lam.12544
Hariharan P, Paul-Satyaseela M, Gnanamani A. In Vitro Profiling of Antimethicillin-resistant Staphylococcus Aureus Activity of Thymoquinone Against Selected Type and Clinical Strains. Lett Appl Microbiol. 2016;62(3):283-9. PubMed PMID: 26743923.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - In vitro profiling of antimethicillin-resistant Staphylococcus aureus activity of thymoquinone against selected type and clinical strains. AU - Hariharan,P, AU - Paul-Satyaseela,M, AU - Gnanamani,A, PY - 2015/10/15/received PY - 2016/01/01/revised PY - 2016/01/02/accepted PY - 2016/1/9/entrez PY - 2016/1/9/pubmed PY - 2016/12/30/medline KW - MRSA KW - Nigella sativa Linn KW - antibacterial KW - phytochemical KW - thymoquinone SP - 283 EP - 9 JF - Letters in applied microbiology JO - Lett Appl Microbiol VL - 62 IS - 3 N2 - UNLABELLED: This study explores antimethicillin-resistant Staphylococcus aureus (MRSA) activity of a bioactive phytochemical constituent, thymoquinone obtained from the medicinal herb, Nigella sativa Linn. Based on initial assessment on crude extract of seeds of Nigella sativa Linn, the pure active constituent was employed in the study. A total of 99 MRSA strains which comprised of 40 types and 59 clinical strains were selected for the study. Minimum inhibitory concentration (MIC), bactericidal activity, postantibiotic effect (PAE) and propensity to select resistant mutants were determined using standard protocols. Results revealed that thymoquinone exhibited MIC in the range of 8-16 μg ml(-1) and MIC90 of 16 μg ml(-1) against MRSA strains. It was bactericidal to MRSA by demonstrating >3 log kill. It showed a longer PAE of 3·2 ± 0·2 h. Upon exposure to high-density inoculum of MRSA, it did not select resistant mutants. Transmission electron microscopy of thymoquinone-treated MRSA showed no lysis but damage to cell wall and cell membrane which corroborated well with the salt tolerance and bacteriolysis assays. In conclusion, MIC90 , bactericidal property, longer PAE, absence of resistant mutant selection and damages in cell membrane and cell wall imply a promising anti-MRSA activity of thymoquinone. SIGNIFICANCE AND IMPACT OF THE STUDY: This is the first detailed report on anti-MRSA activity of thymoquinone. The assessment was made with both type and clinical strains. Thymoquinone may be a potential lead compound which can be further optimized to discover novel anti-MRSA agents. SN - 1472-765X UR - https://www.unboundmedicine.com/medline/citation/26743923/In_vitro_profiling_of_antimethicillin_resistant_Staphylococcus_aureus_activity_of_thymoquinone_against_selected_type_and_clinical_strains_ L2 - https://doi.org/10.1111/lam.12544 DB - PRIME DP - Unbound Medicine ER -